吉非替尼片致暴发性紫癜药品不良反应1例分析  

Analysis of One Case of purpura fulminans Induced by Gefitinib Tablets

作　　者：樊鹏利[1] 鲁乐乐 王漪檬[1] 刘银萍[1] FAN Pengli;LU Lele;WANG Yimeng;LIU Yinping(Department of Pharmacy,Henan Provincial People's Hospital,Zhengzhou 450003,China)

机构地区：[1]河南省人民医院药学部,河南郑州450003

出　　处：《中国药物警戒》2020年第7期441-443,共3页Chinese Journal of Pharmacovigilance

摘　　要：目的探讨吉非替尼片致暴发性紫癜的处置措施,为临床安全合理用药提供参考。方法分析1例治疗肺腺癌服用吉非替尼片致暴发性紫癜患者的诊疗经过,结合文献检索,分析吉非替尼片诱发暴发性紫癜的机制及应对措施。结果患者使用吉非替尼片5天后全身出现暴发性紫癜,立即停用,并给予静脉滴注维生素C、葡萄糖酸钙、甲泼尼龙琥珀酸钠等支持治疗,患者躯干、四肢皮肤瘀点、瘀斑基本消退。结论吉非替尼导致的暴发性紫癜应立即停药,待不良反应改善后,再重新给予EGFR-TKI治疗。Objective To explore the treatment of purpura fulminans induced by gefitinib tablets, so as to provide reference for clinical rational use of drugs. Methods The mechanism and countermeasures of purpura fulminans induced by gefitinib tablets were studied by literature retrieval and analyzing the treatment process of a patient. Results 5 days after taking gefitinib tablets, the patient was diagnosed with purpura fulminans. The drug was stopped immediately so that the symptoms on the patient’s skin were relieved gradually via treatment with vitamin C, calcium gluconate, methylprednisolone sodium succinate and other supportive treatment. Conclusion Gefitinib-induced purpura fulminans should be stopped immediately, and the EGFR-TKI should be given again after the adverse reactions have improved.

关 键 词：吉非替尼 暴发性紫癜 肺腺癌 药品不良反应 

分 类 号：R994.11[医药卫生—毒理学]